drugset

drugset / Trial / NCT02924272

Ixazomib Rollover Study

NCT02924272 ↗

Phase 2 Completed 32 enrolled Takeda Takeda Development Center Americas, Inc. · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to provide continued access to ixazomib and/or other study drugs from an ixazomib parent study.

Timeline

Start: 2016-12-16
Primary completion: 2024-07-03
Completion: 2024-07-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ixazomib	Unknown	—	Oral

Indications